NCT04433156 2026-04-09
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
Henan Cancer Hospital
Phase 2 Completed
Henan Cancer Hospital
University College, London
Hackensack Meridian Health
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
Washington University School of Medicine
Canadian Cancer Trials Group